Market capitalization | $211.06m |
Enterprise Value | $-95.61m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.61 |
EV/Sales (TTM) EV/Sales | -0.32 |
P/S ratio (TTM) P/S ratio | 0.71 |
P/B ratio (TTM) P/B ratio | 0.81 |
Revenue growth (TTM) Revenue growth | 55.71% |
Revenue (TTM) Revenue | $298.76m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
7 Analysts have issued a Amylyx Pharmaceuticals forecast:
7 Analysts have issued a Amylyx Pharmaceuticals forecast:
Jun '24 |
+/-
%
|
||
Revenue | 299 299 |
56%
56%
|
|
Gross Profit | 159 159 |
10%
10%
|
|
EBITDA | -154 -154 |
92%
92%
|
EBIT (Operating Income) EBIT | -155 -155 |
91%
91%
|
Net Profit | -166 -166 |
128%
128%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Josh Klee |
Employees | 384 |
Founded | 2013 |
Website | www.amylyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.